a Child-Pugh liver class A, measurable disease per RECIST v1.1 by BIR, an ECOG performance status of 0 or 1, no main portal vein invasion, and an esophagogastro
Pts with invasion of main portal venous were excluded. Donafenib plus anti-PD-1 antibody was initiated at 4 to 8 weeks after resection and continued for up to six months. No other adjuvant therapies were allowed before enrollment and during the study, except for anti-virus treatment. The ...
The second subgroup, with well-defined HCC nodules and preserved portal flow, is linked to first-line treatment recommendation TACE. The last, with diffuse, infiltrative, extensive bilobar liver involvement, is linked to systemic treatment, similarly to advanced stage (C). These refinements were ...